Bye, Bye Byetta: Teva To Take AstraZeneca's GLP-1 Agonist Generic Two Years Early
This article was originally published in The Pink Sheet Daily
First in class is the first to fall, and Byetta could go even earlier than the October 2017 date set in Teva settlement since AstraZeneca still faces a generic challenge from Amneal – and a direct attack on its patents from Sanofi.
You may also be interested in...
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
US FDA final guidance describes possible study design to test whether selected names may misbrand a drug. Agency also okays use of two-letter USAN stems in product names and clarifies use of modifiers.